Clinical Trial

A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC

Not Yet Recruiting Phase 3
View on ClinicalTrials.gov →
Record status
This record was last updated February 12, 2024 (before its estimated May 1, 2026 completion). Its status may not reflect the trial's current state.
Summary
A phase 3 study to evaluate the efficacy and safety of SY-3505 vs. crizotinib in patients with ALK-positive non-small cell lung cancer who had not received prior systemic therapy.
Trial Details
NCT Number NCT06254599
Lead Sponsor Shouyao Holdings (Beijing) Co. LTD
Conditions Non-small Cell Lung Cancer
Enrollment 255 participants
Start Date 2024-05-01
Primary Completion 2026-05-01 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2024-02-12